Release Therapeutics has developed a patented platform technology that focuses on the local and targeted delivery of highly potent therapeutic proteins, specifically designed for the central nervous system (CNS) and other challenging areas of the body. This innovative approach utilizes a compact cellular innovation involving a small hollow fiber device that is loaded with genetically engineered myoblast cells. The technology is biocompatible, preserving the activity of the encapsulated cells in vivo, and allows for simple and gentle insertion and extraction, minimizing discomfort for patients. It is classified as an Advanced Therapy Medicinal Product (ATMP) and is optimized for long-term locoregional protein delivery, effectively navigating the blood-brain barrier (BBB) to reduce systemic toxicities and adverse effects on other organs.

The company’s pipeline includes several tested products, such as Myo-P3®, Myo-P4®, and Myo-P5®, which target specific genetic disorders. Myo-P3® utilizes ipilimumab to modulate the immune system for advanced melanoma treatment, while Myo-P4® addresses Metachromatic Leukodystrophy by producing Arylsulfatase A to counteract enzyme deficiencies that lead to myelin sheath destruction. Myo-P5® focuses on treating Sanfilippo disease by producing either NAGLU or SGSH. Release Therapeutics has secured multiple regulatory approvals, including from the FDA and Swissmedic, and has established a GMP-validated scalable process to ensure consistent quality and safety in its therapeutic offerings.

Switzerland

Release Therapeutics is a preclinical-stage BioMedTech company developing the first cell macroencapsulation technology designed to deliver potent therapeutic proteins beyond the human blood-brain barrier.

Release Therapeutics

Company Details